Immunotherapy Drugs Market
Description
Immunotherapy Drugs Market Summary
The global immunotherapy drugs market size was estimated at USD 285.73 billion in 2025 and is expected to reach USD 675.98 billion by 2033, growing at a CAGR of 11.41% from 2026 to 2033. This market is primarily driven by the rising incidence of chronic diseases globally.
This market was driven by the rising global burden of cancer and chronic diseases, including autoimmune and inflammatory disorders, alongside the growing limitations of conventional treatments such as chemotherapy and radiation therapy. These constraints had accelerated the shift toward immunotherapy because of its targeted mechanism of action and improved patient outcomes. For instance, February 2025, the World Health Organization reported that cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in six deaths globally. Breast cancer recorded 2.26 million cases, lung cancer 2.21 million, and colorectal cancer 1.93 million, while lung cancer caused 1.80 million deaths. The organization also estimated around 400,000 childhood cancer cases annually and noted that 30 percent of cancers in low and lower middle income countries were infection related, reinforcing demand for advanced immunotherapies.
Technological advancements and robust research activity play a critical role in driving the immunotherapy drugs market forward. Significant progress in immuno-oncology, particularly in immune checkpoint inhibitors, monoclonal antibodies, and cell-based therapies such as CAR-T, has transformed cancer treatment paradigms. These therapies have demonstrated strong efficacy across multiple solid tumors and hematological malignancies, leading to expanding clinical indications. Pharmaceutical and biotechnology companies are investing heavily in research and development to improve therapeutic effectiveness, reduce adverse effects, and develop next-generation immunotherapies. Strategic collaborations, mergers, and acquisitions are also accelerating innovation and pipeline expansion. Moreover, favorable regulatory frameworks, fast-track approvals, and orphan drug designations in major markets are enabling faster commercialization of novel immunotherapy drugs, thereby contributing significantly to market growth.
Beyond oncology, the immunotherapy drugs market was supported by expanding applications and improving healthcare infrastructure worldwide, which broadened overall market potential. Immunotherapies were increasingly explored for autoimmune diseases, infectious diseases, and rare genetic disorders, enabling wider clinical adoption. In developed regions, strong reimbursement systems, higher healthcare spending, and access to advanced diagnostic facilities facilitated routine use of immunotherapy drugs. At the same time, emerging economies experienced steady growth due to improvements in healthcare systems, rising medical tourism, and government initiatives aimed at strengthening cancer care delivery. Growing awareness among patients and healthcare providers, coupled with gradual improvements in the affordability of biologic therapies, further supported uptake. Together, these interconnected factors sustained long term growth prospects and continued innovation in the global immunotherapy drugs market.
Global Immunotherapy Drugs Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immunotherapy drugs market report based on drug type, indication, and region:
The global immunotherapy drugs market size was estimated at USD 285.73 billion in 2025 and is expected to reach USD 675.98 billion by 2033, growing at a CAGR of 11.41% from 2026 to 2033. This market is primarily driven by the rising incidence of chronic diseases globally.
This market was driven by the rising global burden of cancer and chronic diseases, including autoimmune and inflammatory disorders, alongside the growing limitations of conventional treatments such as chemotherapy and radiation therapy. These constraints had accelerated the shift toward immunotherapy because of its targeted mechanism of action and improved patient outcomes. For instance, February 2025, the World Health Organization reported that cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in six deaths globally. Breast cancer recorded 2.26 million cases, lung cancer 2.21 million, and colorectal cancer 1.93 million, while lung cancer caused 1.80 million deaths. The organization also estimated around 400,000 childhood cancer cases annually and noted that 30 percent of cancers in low and lower middle income countries were infection related, reinforcing demand for advanced immunotherapies.
Technological advancements and robust research activity play a critical role in driving the immunotherapy drugs market forward. Significant progress in immuno-oncology, particularly in immune checkpoint inhibitors, monoclonal antibodies, and cell-based therapies such as CAR-T, has transformed cancer treatment paradigms. These therapies have demonstrated strong efficacy across multiple solid tumors and hematological malignancies, leading to expanding clinical indications. Pharmaceutical and biotechnology companies are investing heavily in research and development to improve therapeutic effectiveness, reduce adverse effects, and develop next-generation immunotherapies. Strategic collaborations, mergers, and acquisitions are also accelerating innovation and pipeline expansion. Moreover, favorable regulatory frameworks, fast-track approvals, and orphan drug designations in major markets are enabling faster commercialization of novel immunotherapy drugs, thereby contributing significantly to market growth.
Beyond oncology, the immunotherapy drugs market was supported by expanding applications and improving healthcare infrastructure worldwide, which broadened overall market potential. Immunotherapies were increasingly explored for autoimmune diseases, infectious diseases, and rare genetic disorders, enabling wider clinical adoption. In developed regions, strong reimbursement systems, higher healthcare spending, and access to advanced diagnostic facilities facilitated routine use of immunotherapy drugs. At the same time, emerging economies experienced steady growth due to improvements in healthcare systems, rising medical tourism, and government initiatives aimed at strengthening cancer care delivery. Growing awareness among patients and healthcare providers, coupled with gradual improvements in the affordability of biologic therapies, further supported uptake. Together, these interconnected factors sustained long term growth prospects and continued innovation in the global immunotherapy drugs market.
Global Immunotherapy Drugs Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immunotherapy drugs market report based on drug type, indication, and region:
- Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
- Monoclonal Antibodies
- Immunomodulator
- Vaccine
- Others
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Thailand
- South Korea
- Australia
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
100 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Primary User
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Osteoarthritis Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- Chapter 4. Osteoarthritis Therapeutics Market: Product Business Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Viscosupplements
- 4.4.1. Viscosupplements Market, 2021 - 2033 (USD Million)
- 4.5. Platelet-Rich Plasma (PRP) Therapy
- 4.5.1. Platelet-Rich Plasma (PRP) Therapy Market, 2021 - 2033 (USD Million)
- 4.6. Bone Graft Substitutes
- 4.6.1. Bone Graft Substitutes Market, 2021 - 2033 (USD Million)
- 4.7. BMAC (Bone Marrow Aspirate Concentrate) Therapy
- 4.7.1. BMAC (Bone Marrow Aspirate Concentrate) Therapy Market, 2021 - 2033 (USD Million)
- 4.8. Adipose Tissue Therapy
- 4.8.1. Adipose Tissue Therapy Market, 2021 - 2033 (USD Million)
- 4.9. Autologous Chondrocyte Implantation (ACI), Including MACI
- 4.9.1. Autologous Chondrocyte Implantation (ACI), Including MACI Market, 2021 - 2033 (USD Million)
- 4.10. Stem Cell (other)
- 4.10.1. Stem Cell (other) Market, 2021 - 2033 (USD Million)
- 4.11. Others
- 4.11.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 5. Osteoarthritis Therapeutics Market: Application Business Analysis
- 5.1. Application Market Share, 2025 & 2033
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by application, 2021 to 2033 (USD Million)
- 5.4. Knee Osteoarthritis
- 5.4.1. Knee Osteoarthritis Market, 2021 - 2033 (USD Million)
- 5.5. Hip Osteoarthritis
- 5.5.1. Hip Osteoarthritis Market, 2021 - 2033 (USD Million)
- 5.6. Shoulder Osteoarthritis
- 5.6.1. Shoulder Osteoarthritis Market, 2021 - 2033 (USD Million)
- 5.7. Spine Osteoarthritis
- 5.7.1. Spine Osteoarthritis Market, 2021 - 2033 (USD Million)
- 5.8. Ankle & Foot Osteoarthritis
- 5.8.1. Ankle & Foot Osteoarthritis Market, 2021 - 2033 (USD Million)
- 5.9. Others
- 5.9.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 6. Osteoarthritis Therapeutics Market: Primary User Business Analysis
- 6.1. Primary User Market Share, 2025 & 2033
- 6.2. Primary User Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by primary user, 2021 to 2033 (USD Million)
- 6.4. Orthopedic Surgeons
- 6.4.1. Orthopedic Surgeons Market, 2021 - 2033 (USD Million)
- 6.5. Rheumatologists
- 6.5.1. Rheumatologists Market, 2021 - 2033 (USD Million)
- 6.6. Sports Medicine Specialists
- 6.6.1. Sports Medicine Specialists Market, 2021 - 2033 (USD Million)
- 6.7. Regenerative Medicine Specialists
- 6.7.1. Regenerative Medicine Specialists Market, 2021 - 2033 (USD Million)
- 6.8. Others
- 6.8.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 7. Osteoarthritis Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Osteoarthritis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Application Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Application Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. U.S. Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Application Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Application Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. Uk Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Application Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Application Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Application Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Application Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Application Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Application Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Application Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Application Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Application Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Application Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Application Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Application Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Application Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Application Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Japan Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Application Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. China Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Application Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Application Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Application Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Application Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Osteoarthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Stryker
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Zimmer Biomet Holdings, Inc.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Medtronic
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Anika Therapeutics, Inc.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Bioventus
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Vericel Corporation
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Smith & Nephew
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Fidia Farmaceutici S.p.A.
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Seikagaku Corporation
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Sanofi
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
